Outcomes for Dostarlimab and Real-World Treatments in Post-platinum Patients With Advanced/Recurrent Endometrial Cancer: The GARNET Trial Versus a US Electronic Health Record-Based External Control Arm

Background: Patients with advanced or recurrent endometrial cancer (EC) have limited treatment options following platinum-based chemotherapy and poor prognosis. The single-arm, Phase I GARNET trial (NCT02715284) previously reported dostarlimab efficacy in mismatch repair–deficient/microsatellite ins...

Descripción completa

Detalles Bibliográficos
Autores principales: Goulden, Scott, Shen, Qin, Coleman, Robert L., Mathews, Cara, Hunger, Matthias, Pahwa, Ankit, Schade, Rene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Columbia Data Analytics, LLC 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10493167/
https://www.ncbi.nlm.nih.gov/pubmed/37701519
http://dx.doi.org/10.36469/001c.77484

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10493167/
https://www.ncbi.nlm.nih.gov/pubmed/37701519
http://dx.doi.org/10.36469/001c.77484

Ejemplares similares